$VIRX
Viracta Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020039326 Filed on August 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.060M $2.520M $2.440M
YoY Change -18.25% -10.64% -27.38%
% of Gross Profit
Research & Development $3.361M $3.680M $3.248M
YoY Change -8.67% -2.13% -18.17%
% of Gross Profit
Depreciation & Amortization $0.00 $2.000K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $4.240M $6.210M $3.248M
YoY Change -31.72% -5.65% -18.17%
Operating Profit -$4.240M -$6.206M
YoY Change -31.68% -5.71%
Interest Expense $65.00K $111.0K -$260.0K
YoY Change -41.44% -61.32% -192.53%
% of Operating Profit
Other Income/Expense, Net $0.00 $76.00K $90.00K
YoY Change -100.0% 162.07% -9.09%
Pretax Income -$6.390M -$6.240M -$5.860M
YoY Change 2.4% -8.77% -19.39%
Income Tax
% Of Pretax Income
Net Earnings -$4.236M -$6.241M -$5.860M
YoY Change -32.13% -8.76% -19.43%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.009M -$3.029M -$3.467M
COMMON SHARES
Basic Shares Outstanding 67.58M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.70M $12.20M $24.80M
YoY Change 45.08% -40.2% -2.36%
Cash & Equivalents $23.20M $9.797M $24.81M
Short-Term Investments $2.400M
Other Short-Term Assets $7.200M $7.700M $1.600M
YoY Change -6.49% 413.33% 6.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.90M $19.84M $26.40M
YoY Change 25.49% -9.4% -1.86%
LONG-TERM ASSETS
Property, Plant & Equipment $500.0K $7.000K $1.200M
YoY Change 7042.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $96.00K $105.0K $100.0K
YoY Change -8.57% 5.0% 0.0%
Total Long-Term Assets $606.0K $1.202M $1.400M
YoY Change -49.58% 1102.0% 1300.0%
TOTAL ASSETS
Total Short-Term Assets $24.90M $19.84M $26.40M
Total Long-Term Assets $606.0K $1.202M $1.400M
Total Assets $25.51M $21.04M $27.80M
YoY Change 21.2% -4.35% 2.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $452.0K $692.0K $900.0K
YoY Change -34.68% -56.75% -10.0%
Accrued Expenses $3.500M $2.600M $3.100M
YoY Change 34.62% -18.75% -6.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.500M $5.500M $6.000M
YoY Change 0.0% -24.66% -17.81%
Total Short-Term Liabilities $9.400M $8.743M $10.00M
YoY Change 7.51% -27.14% -13.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $17.00K $700.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $17.00K $700.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.400M $8.743M $10.00M
Total Long-Term Liabilities $0.00 $17.00K $700.0K
Total Liabilities $9.400M $9.305M $10.67M
YoY Change 1.02% -22.46% -8.03%
SHAREHOLDERS EQUITY
Retained Earnings -$695.0M -$671.6M
YoY Change 3.48%
Common Stock $11.00K $7.000K
YoY Change 57.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$36.87M $11.74M $17.09M
YoY Change
Total Liabilities & Shareholders Equity $25.51M $21.04M $27.80M
YoY Change 21.2% -4.35% 2.96%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$4.236M -$6.241M -$5.860M
YoY Change -32.13% -8.76% -19.43%
Depreciation, Depletion And Amortization $0.00 $2.000K
YoY Change 0.0%
Cash From Operating Activities -$5.800M -$6.900M -$6.113M
YoY Change -15.94% 16.95% -6.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.450M -$2.390M $0.00
YoY Change -244.35% -473.44% -100.0%
Cash From Investing Activities $3.450M -$2.390M $0.00
YoY Change -244.35% -473.44% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.69M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K -240.0K 17.23M
YoY Change -108.33% -126.09% 8689.8%
NET CHANGE
Cash From Operating Activities -5.800M -6.900M -6.113M
Cash From Investing Activities 3.450M -2.390M 0.000
Cash From Financing Activities 20.00K -240.0K 17.23M
Net Change In Cash -2.330M -9.530M 11.12M
YoY Change -75.55% 119.59% -298.06%
FREE CASH FLOW
Cash From Operating Activities -$5.800M -$6.900M -$6.113M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
817000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
98000
CY2019Q4 us-gaap Assets
Assets
37240000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
791000
CY2019Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
521000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
985000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1109000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5465000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9400000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9416000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2019Q4 us-gaap Liabilities
Liabilities
9697000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
11769000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
698562000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-694965000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-682800000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
16106000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
27543000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
96000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
5500000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16364000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1697000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
36322000
us-gaap Operating Expenses
OperatingExpenses
12263000
CY2020Q2 us-gaap Assets
Assets
25506000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
452000
CY2020Q2 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
402000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
692000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1836000
CY2020Q2 us-gaap Notes Payable Current
NotesPayableCurrent
5473000
CY2020Q2 us-gaap Liabilities
Liabilities
9400000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
11769000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
699291000
us-gaap Operating Expenses
OperatingExpenses
11893000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6206000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12143000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11893000
CY2020Q2 us-gaap Interest Expense
InterestExpense
65000
us-gaap Interest Expense
InterestExpense
135000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
76000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4962000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2386000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
164000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6390000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6241000
us-gaap Net Income Loss
NetIncomeLoss
-12165000
us-gaap Net Income Loss
NetIncomeLoss
-12101000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6241000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12166000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12101000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72190000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
111405000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65702000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Profit Loss
ProfitLoss
-12101000
us-gaap Share Based Compensation
ShareBasedCompensation
811000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13007000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25506000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37240000
CY2019Q2 us-gaap Interest Expense
InterestExpense
111000
us-gaap Interest Expense
InterestExpense
372000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
113000
us-gaap Profit Loss
ProfitLoss
-12165000
us-gaap Share Based Compensation
ShareBasedCompensation
706000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-41000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
4000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11538000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
747000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17154000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16407000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2386000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5453000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7500000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
7879000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10662000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
464000
snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
23000
snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
36000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16994000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4892000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18261000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13696000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23153000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
21762000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1362000
snss Legal Expenses Accrued As Cost Of Equity Financing
LegalExpensesAccruedAsCostOfEquityFinancing
-5000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
22086000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
23000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
387000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
17086000
CY2019Q2 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
464000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
36000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
394000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
11739000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
23000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
706000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3993000
snss Issuance Of Common And Preferred Stock In Underwritten Offering Net Of Issuance Costs
IssuanceOfCommonAndPreferredStockInUnderwrittenOfferingNetOfIssuanceCosts
18536000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
54000
snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
464000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
36000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
757000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6390000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
111416000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1601000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15297000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s condensed consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to <font style="color:#000000;">valuation of marketable securities, equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting</font>. </p>
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10293000
CY2019Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
16363000
CY2019Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
1000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23200000
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27828000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27828000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16551000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16551000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
26656000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26657000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10293000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2019 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2020Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q2 us-gaap Notes Payable
NotesPayable
5500000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
387000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
394000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
706000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
811000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
294000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
294000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
588000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
43000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
545000
CY2020Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000

Files In Submission

Name View Source Status
0001564590-20-039326-index-headers.html Edgar Link pending
0001564590-20-039326-index.html Edgar Link pending
0001564590-20-039326.txt Edgar Link pending
0001564590-20-039326-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwr3lur3wetk000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20200630.htm Edgar Link pending
snss-20200630.xml Edgar Link completed
snss-20200630.xsd Edgar Link pending
snss-20200630_cal.xml Edgar Link unprocessable
snss-20200630_def.xml Edgar Link unprocessable
snss-20200630_lab.xml Edgar Link unprocessable
snss-20200630_pre.xml Edgar Link unprocessable
snss-ex101_13.htm Edgar Link pending
snss-ex102_12.htm Edgar Link pending
snss-ex311_9.htm Edgar Link pending
snss-ex321_8.htm Edgar Link pending